Understanding the role of obesity in endocrine therapy for postmenopausal breast cancer: significance of the BIG 1–98 and ATAC trial data
Abstract Obesity is a known risk factor for poor breast cancer outcomes, but its impact on endocrine therapy efficacy remains unclear. While the ATAC trial suggests reduced effectiveness of aromatase inhibitors (AIs) in women with obesity, the BIG 1–98 trial found no significant differences. Clinica...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Springer
2025-07-01
|
| Colección: | Discover Oncology |
| Acceso en línea: | https://doi.org/10.1007/s12672-025-02857-w |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|